CNSP News and Press, CNS Pharmaceuticals Inc. From 04/11/22

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier The blood-brain barrier ordi...

CNS Pharmaceuticals (NASDAQ:CNSP) said on Wednesday that it received approval from National Agency for the Safety of Medicine and Health Products and the People Protection Ethics Committee SUD-EST III in France to conduct a study of Berubicin to treat recurrent glioblastom...

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) PR Newswire Company continues to drive global patient enrollment in pivotal study of...

Penny stocks are at the top of the minds of thousands of investors in the stock market today. Even with broader markets trading lower ahead of tomorrow’s Fed minutes, traders are looking to capitalize on the wild volatility that has come into play. One of the areas of the penny stock...

CNS Pharmaceuticals [[CNSP, +27%]] on Tuesday said it received approval from Swiss drug regulator Swissmedic to conduct a study of Berubicin to treat recurrent glioblastoma multiforme (GBM), an aggressive type of brain cancer. The anti-cancer treatment developer said it has alr...

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) PR Newswire Company previously received approval from swissethics, the umbrella organization of t...

The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively CNS initiated a potentially pivotal...

A new study has found that children with brain tumors, particularly those who are three months and younger, have a significantly lower rate of survival in comparison to those aged between 1 and 19. The study was carried out by researchers at the University of Colorado Cancer Center, led by...

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin ...

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“...